Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
BCLI

BCLI - BrainStorm Cell Therapeutics Inc Stock Price, Fair Value and News

0.42USD+0.02 (+5.00%)Delayed

Market Summary

BCLI
USD0.42+0.02
Delayed
5.00%

BCLI Stock Price

View Fullscreen

BCLI RSI Chart

BCLI Valuation

Market Cap

29.4M

Price/Earnings (Trailing)

-1.89

Price/Free Cashflow

-1.51

BCLI Price/Sales (Trailing)

BCLI Profitability

Return on Equity

279.89%

Return on Assets

-463.98%

Free Cashflow Yield

-66.43%

BCLI Fundamentals

BCLI Earnings

Earnings (TTM)

-15.5M

Earnings Growth (Yr)

32.77%

Earnings Growth (Qtr)

39.03%

Breaking Down BCLI Revenue

Last 7 days

13.5%

Last 30 days

-8.7%

Last 90 days

-27.6%

Trailing 12 Months

-79%

How does BCLI drawdown profile look like?

BCLI Financial Health

Current Ratio

0.18

BCLI Investor Care

Shares Dilution (1Y)

77.83%

Diluted EPS (TTM)

-0.31

Tracking the Latest Insider Buys and Sells of BrainStorm Cell Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 24, 2024
hartounian hartoun
acquired
-
-
30,000
evp, chief operating officer
May 28, 2024
lebovits chaim
acquired
7,774
0.5183
15,000
president & ceo
May 22, 2024
lebovits chaim
acquired
16,000
0.64
25,000
president & ceo
May 21, 2024
lebovits chaim
acquired
14,475
0.579
25,000
president & ceo
May 13, 2024
lebovits chaim
acquired
4,900
0.49
10,000
president & ceo
May 11, 2024
lebovits chaim
acquired
4,665
0.4665
10,000
president & ceo
May 10, 2024
lebovits chaim
acquired
9,300
0.465
20,000
president & ceo

1–10 of 50

Which funds bought or sold BCLI recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 12, 2024
Weaver Consulting Group
added
17.56
-33,247
79,330
0.03%
Jul 10, 2024
First Affirmative Financial Network
reduced
-6.45
-3,789
4,838
-%
Jul 09, 2024
KINGSWOOD WEALTH ADVISORS, LLC
sold off
-100
-45,768
-
-%
Jul 08, 2024
ST GERMAIN D J CO INC
unchanged
-
-113
169
-%
Jul 05, 2024
INSTITUTIONAL & FAMILY ASSET MANAGEMENT, LLC
unchanged
-
-1,357
2,031
-%
Jun 11, 2024
EverSource Wealth Advisors, LLC
unchanged
-
222
803
-%
May 20, 2024
Virtu Financial LLC
sold off
-100
-19,000
-
-%
May 17, 2024
Ikarian Capital, LLC
unchanged
-
26,324
50,960
0.01%
May 16, 2024
JANE STREET GROUP, LLC
new
-
10,578
10,578
-%
May 15, 2024
Tower Research Capital LLC (TRC)
reduced
-39.65
1,240
6,218
-%

1–10 of 41

Are Funds Buying or Selling BCLI?

Are funds buying BCLI calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own BCLI
No. of Funds

Unveiling BrainStorm Cell Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 12, 2024
ness kevin dean
6.25%
3,060,000
SC 13G/A
Apr 05, 2023
ness kevin dean
9.98%
3,660,000
SC 13G/A
Feb 14, 2022
abbhi investments, llc
6.69%
2,425,853
SC 13G
Feb 04, 2022
ness kevin dean
9.1%
3,300,000
SC 13G
Jul 12, 2021
blackrock inc.
1.3%
474,347
SC 13G/A
Feb 02, 2021
blackrock inc.
6.1%
1,920,340
SC 13G
May 08, 2020
daly joseph patrick
3.66%
1,077,500
SC 13D/A
Apr 08, 2020
abbhi investments, llc
9.03%
2,367,751
SC 13D
Mar 18, 2020
abbhi investments, llc
9.03%
2,367,751
SC 13G
Nov 21, 2019
daly joseph patrick
4.58%
1,035,181
SC 13D

Recent SEC filings of BrainStorm Cell Therapeutics Inc

View All Filings
Date Filed Form Type Document
Jun 28, 2024
424B5
Prospectus Filed
Jun 28, 2024
8-K
Current Report
Jun 27, 2024
424B5
Prospectus Filed
Jun 26, 2024
8-K
Current Report
Jun 25, 2024
3
Insider Trading
Jun 25, 2024
4
Insider Trading
Jun 20, 2024
8-K
Current Report
Jun 04, 2024
8-K
Current Report
Jun 03, 2024
4
Insider Trading
May 23, 2024
4
Insider Trading

Peers (Alternatives to BrainStorm Cell Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
46.5B
6.8B
-17.79% -4.08%
-7.8
6.8
-64.45% -224.75%
33.0B
2.0B
63.81% 27.79%
-99.24
16.45
75.20% 68.82%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
16.2B
2.5B
0.60% -0.76%
78.61
6.53
13.74% 186.89%
14.3B
3.8B
6.19% 2.76%
19.17
3.79
8.58% 129.81%
MID-CAP
5.1B
107.9M
-5.51% 56.56%
-9.28
48.09
54.84% -28.31%
4.8B
524.1M
-6.99% -54.02%
-11.5
9.15
394.93% 39.61%
3.9B
251.0M
15.74% 13.44%
-13.27
15.67
73.58% -86.73%
3.5B
240.7M
9.12% -18.47%
-7.38
12.77
-1.03% -213.92%
2.9B
813.8M
15.55% -31.16%
-1.7K
3.61
56.43% 98.83%
1.8B
996.6M
-17.40% 41.77%
-4.61
1.85
-26.66% 65.49%
SMALL-CAP
2.0B
411.3M
7.18% 31.22%
30.04
4.76
60.38% -34.49%
628.3M
881.7K
14.71% 639.50%
-18.61
481.06
-77.61% 33.36%
293.1M
4.2M
19.30% 68.30%
-2.35
70.45
-66.30% 48.24%
21.0M
2.1M
-4.31% -79.32%
-0.91
7.61
-13.45% 69.54%

BrainStorm Cell Therapeutics Inc News

Latest updates
Defense World35 hours ago

BrainStorm Cell Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet
(In Thousands)
Balance Sheet
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-20.4%3,3484,2085,6825,7477,8728,45113,25418,96125,79129,27734,53842,23548,57151,25932,69119,22118,0716,5347,8118,86411,851
  Current Assets-33.7%1,2591,8991,5391,2132,9293,1067,50212,80619,26023,28027,94435,18741,03043,24230,33716,62815,2053,3604,6725,5358,257
    Cash Equivalents-40.1%7791,3001,2225462,0217724,1449,00515,15118,85625,69530,56535,93337,82924,77012,15312,4715362,0951,1263,238
  Net PPE-9.3%6226867527998669331,0031,0721,1241,1891,2241,0541,0881,119950918918960664599611
Liabilities-1.9%8,8989,0668,2649,62912,71211,46611,86611,11011,3049,9359,61212,06312,37015,7956,7139,3999,06018,75714,58813,38011,525
  Current Liabilities-12.4%6,8317,8006,3217,69110,4228,8008,9487,8467,3726,3175,8468,0598,19111,2336,4298,8408,25217,65411,95810,5438,480
Shareholder's Equity-14.2%-5,550-4,858---4,840-3,0151,3887,85114,48719,34224,92630,17236,20135,46425,9789,8229,011---326
  Retained Earnings-1.4%-218,000-215,013-209,000-208,000-203,000-197,821-192,803-185,945-178,904-173,544-167,000-162,018-155,749-149,087-137,272-132,784-125,390-117,276-109,584-103,950-99,050
  Additional Paid-In Capital1.3%212,967210,258206,957204,431198,144194,910194,295193,900193,495192,990192,384192,294192,054184,655163,238142,594134,389105,042102,79699,42398,325
Shares Outstanding13.2%68,44760,48945,31540,92736,73536,69436,49336,48636,43736,40136,30536,05635,791--------
Float--------78,887---119,594---278,375---75,374-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations6.8%-3,063-3,285-6,409-6,778-3,986-4,648-4,850-6,134-3,688-5,508-6,460-5,329-8,968-7,578-6,924-5,662-15,029-3,278-3,626-3,508-835
  Share Based Compensation-170---4.00----------------
Cashflow From Investing-100.0%-196-12.004.002,0051,038-11.00-12.00-17.00-1,2971,696-39.00-37.00-302-86.00-2,070-1,994-3451,4391,3913,131
Cashflow From Financing-24.3%2,5393,3527,0975,2993,230-----34.00-106-7,10920,93919,6277,41428,9582,0643,1565.00-
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

BCLI Income Statement

2024-03-31
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating expenses:  
Research and development, net$ 961$ 2,924
General and administrative1,5132,227
Operating loss(2,474)(5,151)
Financial income, net1392
Loss on change in fair value of Warrants liability (Note 6)(940) 
Net loss$ (3,401)$ (5,059)
Basic net loss per share from continuing operations$ (0.05)$ (0.14)
Diluted net loss per share from continuing operations$ (0.05)$ (0.14)
Weighted average number of shares outstanding used in computing basic net loss per share64,738,54436,735,435
Weighted average number of shares outstanding used in computing diluted net loss per share64,738,54436,735,435

BCLI Balance Sheet

2024-03-31
INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current Assets:  
Cash and cash equivalents$ 779$ 1,300
Other accounts receivable2651
Prepaid expenses and other current assets (Note 4)454548
Total current assets1,2591,899
Long-Term Assets:  
Prepaid expenses and other long-term assets2022
Restricted Cash182185
Operating lease right of use asset (Note 5)1,2651,416
Property and Equipment, Net622686
Total Long-Term Assets2,0892,309
Total assets3,3484,208
Current Liabilities:  
Accounts payables4,6904,954
Accrued expenses6361,240
Operating lease liability (Note 5)588603
Employees related liability9171,003
Total current liabilities6,8317,800
Long-Term Liabilities:  
Operating lease liability (Note 5)533672
Warrants liability (Note 6)1,534594
Total long-term liabilities2,0671,266
Total liabilities8,8989,066
Stockholders' Deficit:  
Stock capital: (Note 7) Common Stock of $0.00005 par value - Authorized: 100,000,000 shares at March 31, 2024 and December 31, 2023 respectively; Issued and outstanding: 68,447,193 and 60,489,208 shares at March 31, 2024 and December 31, 2023 respectively.1313
Additional paid-in-capital212,967210,258
Treasury stocks(116)(116)
Accumulated deficit(218,414)(215,013)
Total stockholders' deficit(5,550)(4,858)
Total liabilities and stockholders' deficit$ 3,348$ 4,208
BCLI
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
 CEO
 WEBSITEbrainstorm-cell.com
 INDUSTRYBiotechnology
 EMPLOYEES44

BrainStorm Cell Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for BrainStorm Cell Therapeutics Inc? What does BCLI stand for in stocks?

BCLI is the stock ticker symbol of BrainStorm Cell Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of BrainStorm Cell Therapeutics Inc (BCLI)?

As of Fri Jul 12 2024, market cap of BrainStorm Cell Therapeutics Inc is 29.43 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BCLI stock?

You can check BCLI's fair value in chart for subscribers.

What is the fair value of BCLI stock?

You can check BCLI's fair value in chart for subscribers. The fair value of BrainStorm Cell Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of BrainStorm Cell Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BCLI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is BrainStorm Cell Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether BCLI is over valued or under valued. Whether BrainStorm Cell Therapeutics Inc is cheap or expensive depends on the assumptions which impact BrainStorm Cell Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BCLI.

What is 5 year return on BrainStorm Cell Therapeutics Inc's stock?

In the past 10 years, BrainStorm Cell Therapeutics Inc has provided -0.228 (multiply by 100 for percentage) rate of return.